完整空腹胰岛素可识别无糖尿病患者的非酒精性脂肪肝
本研究在180例患者中评估质谱法测定的完整胰岛素分子对非酒精性脂肪肝(NAFLD)的预测价值。无糖尿病患者中,完整空腹胰岛素预测NAFLD的AUC为0.90(0.84-0.96),优于放射免疫法(AUC 0.80,P=0.007),与ALT联合后AUC达0.94(0.89-0.99),阳性预测值93%、阴性预测值88%。
要点
- 无糖尿病患者中完整空腹胰岛素预测NAFLD的AUC为0.90。
- 完整空腹胰岛素优于放射免疫法测定的胰岛素及其他临床变量。
- 完整空腹胰岛素联合ALT检测NAFLD的AUC达0.94。
核心结论
- 在无糖尿病患者中,质谱法准确测定空腹完整胰岛素水平是一种简便无创的预测NAFLD存在的策略。
研究设计与样本
- 研究纳入180例患者(67%男性,年龄52±11岁,BMI 33.2±5.7 kg/m2),其中46%有糖尿病、65%有NAFLD,患者接受2小时口服葡萄糖耐量试验(OGTT)、肝脏磁共振波谱(1H-MRS),若诊断NAFLD则行经皮肝活检,并用质谱法测量完整胰岛素和C肽分子。
主要发现
- 无论糖尿病状态如何,NAFLD患者的完整空腹胰岛素均较高。
- 无糖尿病的NAFLD患者在OGTT期间胰岛素分泌较其他所有亚组增加约4倍(P=0.008)。
- 完整空腹胰岛素预测无糖尿病患者NAFLD的AUC为0.90(0.84-0.96),显著优于放射免疫法测定的胰岛素(AUC 0.80 [0.71-0.89];P=0.007)。
- 完整空腹胰岛素优于其他临床变量(如天冬氨酸转氨酶、甘油三酯、高密度脂蛋白、血糖、HbA1c和BMI)预测NAFLD。
- 完整胰岛素×ALT联合检测NAFLD的AUC为0.94(0.89-0.99),阳性和阴性预测值分别为93%和88%,显著优于NAFLD-LFS(P=0.009)、HSI(P<0.001)和TyG指数(P=0.039)。
临床怎么用
- 在无糖尿病患者中,可考虑采用质谱法测定空腹完整胰岛素水平来无创预测NAFLD的存在。
- 完整空腹胰岛素与ALT联合可提高对NAFLD的预测效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with nonalcoholic fatty liver disease (NAFLD) are characterized by insulin resistance and hyperinsulinism. However, insulin resistance measurements have not been shown to be good diagnostic tools to predict NAFLD in prior studies. OBJECTIVE: We aimed to assess a newly validated method to measure intact molecules of insulin by mass spectrometry to predict NAFLD. METHODS: Patients underwent a 2-hour oral glucose tolerance test (OGTT), a liver magnetic resonance spectroscopy (1H-MRS), and a percutaneous liver biopsy if they had a diagnosis of NAFLD. Mass spectrometry was used to measure intact molecules of insulin and C-peptide. RESULTS: A total of 180 patients were recruited (67% male; 52 ± 11 years of age; body mass index [BMI] 33.2 ± 5.7 kg/m2; 46% with diabetes and 65% with NAFLD). Intact fasting insulin was higher in patients with NAFLD, irrespective of diabetes status. Patients with NAFLD without diabetes showed ~4-fold increase in insulin secretion during the OGTT compared with all other subgroups (P = 0.008). Fasting intact insulin measurements predicted NAFLD in patients without diabetes (area under the receiver operating characteristic curve [AUC] of 0.90 [0.84-0.96]). This was significantly better than measuring insulin by radioimmunoassay (AUC 0.80 [0.71-0.89]; P = 0.007). Intact fasting insulin was better than other clinical variables (eg, aspartate transaminase, triglycerides, high-density lipoprotein, glucose, HbA1c, and BMI) to predict NAFLD. When combined with alanine transaminase (ALT) (intact insulin × ALT), it detected NAFLD with AUC 0.94 (0.89-0.99) and positive and negative predictive values of 93% and 88%, respectively. This newly described approach was significantly better than previously validated noninvasive scores such as NAFLD-LFS (P = 0.009), HSI (P < 0.001), and TyG index (P = 0.039). CONCLUSION: In patients without diabetes, accurate measurement of fasting intact insulin levels by mass spectrometry constitutes an easy and noninvasive strategy to predict presence of NAFLD.
引用
- Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. J Clin Endocrinol Metab. 2021. PMID: 34190318. doi:10.1210/clinem/dgab417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。